PerkinElmer to unveil innovative cancer research solutions at AACR meeting
“PPMD is excited that the team at PerkinElmer will be providing the newborn screening assay for our recently launched newborn screening program,” said Pat Furlong, President & CEO, PPMD, the largest and most comprehensive nonprofit organization in the U.S. focused on ending Duchenne. “We believe that potential Duchenne treatments will benefit from early interventions and are grateful to collaborators like PerkinElmer, ACMG, through the NIH-funded Newborn Screening Translational Research Network (NBSTRN), and the State of New York for their participation at this critical moment in Duchenne therapy development. I am a firm believer that knowledge is power in our fight to end the progression of this deadly disorder. Early diagnosis will mean early intervention.”
New York State recently screened the first infant for Duchenne as part PPMD's Newborn Screening Pilot. PerkinElmer is collaborating with the New York State Department of Health on a two-year project that will screen approximately 100,000 infants using its GSP CK-MM assay. Results from the state’s Duchenne screening pilot will provide options for new and early treatments, helping to lay the framework for further Duchenne newborn screening programs in the U.S. and globally.
As the global leader in newborn screening, we’re excited to play an integral role on this innovative program to advance detection of Duchenne. Screening newborns ensures timely treatment for a disease that may otherwise go undetected for years, affording them a better chance at improved health outcomes.” Petra Furu, Ph.D., General Manager, Reproductive Health, PerkinElmer Source:
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology